Stamford, CT -- (SBWIRE) -- 01/28/2014 -- Wall Street Pennies is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Advanced Cell Technology, Inc. (OTCMKTS:ACTC), Peregrine Pharmaceuticals (NASDAQ:PPHM), Dynavax Technologies Corporation (NASDAQ:DVAX), Synovus Financial Corp. (NYSE:SNV).
Advanced Cell Technology, Inc. (OTCMKTS:ACTC) opened its last trade at the price of $0.06. Its closing price was $0.0740 after gaining 25.21% for the day. The company traded with the total volume of 72.92 million shares, while its average trading volume remained 7.74 million shares. The beta of this stock stands at -3.99. Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. The company is conducting various clinical trials for treating macular degeneration, and has a preclinical development pipeline focused on products for eye diseases.
For How Long ACTC will Fight for Profitability? Read This Trend Analysis report
Peregrine Pharmaceuticals (NASDAQ:PPHM) percentage change plunged -7.18% to close at $1.68 with the total traded volume of 4.46 million shares, along with average volume of 4.10 million shares. The 52 week range of the stock remained $1.11 - $2.43, while its day lowest price was $1.66. The share price hit the day highest price of $1.85. Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of monoclonal antibodies focused on the treatment and diagnosis of cancer. The company’s lead product candidates in development include Bavituximab, a phosphatidylserine (PS) targeting agent that completed Phase IIb second-line non-small cell lung cancer trial for the treatment of solid tumors.
Has PPHM Found The Bottom And Ready To Gain Momentum? Find Out Here
Dynavax Technologies Corporation (NASDAQ:DVAX) traded on volume of 11.73 million shares in the last session against average volume of 5.25 million shares. The company started its trading session with the price of $1.85 and closed at $1.77 by scoring -4.84%. Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences.
Why Should Investors Buy DVAX After the Recent Fall? Just Go Here and Find Out
Synovus Financial Corp. (NYSE:SNV) started its last trading session with the price of $3.49 and closed at $3.45 by scoring -0.86%. The stock traded with total volume of 10.78 million shares, while the average trading volume remained 7.93 million shares. The beta value of this stock stands at 1.99. Day range for the stock was $3.36 - $3.49. Synovus financial corp., a financial services and bank holding company, provides integrated financial services. Its integrated financial services include commercial and retail banking, financial management, insurance, and mortgage services.
Will SNV Get Buyers Even After The Recent Rally? Find Out Here
About Wall Street Pennies:
Wall Street Pennies is always penetrating the market every day for enormous penny stock runs before they happen in order to assist its customers. Our Penny Stock Newsletter also offers free market strategies and analysis from one of the most experienced and well-respected chartists in the penny stock industry.
Carriage Consulting Group, www.wallstreetpennies.com,, their Members, officers, directors, employees, affiliates, or any other related person(s) (collectively, “www.wallstreetpennies.com,”) are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. Wall Street Pennies as defined are neither licensed nor qualified to provide investment advice and you are specifically and adamantly advised not to rely upon anything said/posted/communicated/implied or expressed by www.wallstreetpennies.com, as defined.
Read full Disclaimer at: http://wallstreetpennies.com/financial-disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)